phase readout

NCT01274338: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

ACTIVE_NOT_RECRUITINGupdated 20d ago

community read0 votes

Sponsor: National Cancer Institute (NCI). Phase: PHASE3. Conditions: Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7

view source ↗

NCT01274338: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Report a data issue

comments(0)